drugset / Trial / NCT04968106
Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Sarcomas (TORNADO)
Phase 2
Active not recruiting
66 enrolled
Institut Bergonié
Incyte Biosciences International Sàrl · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Multicenter, prospective, open-labeled, 2-arm, non-comparative randomized phase II trial to assess the antitumor activity of retifanlimab (INCMGA00012) in association with neoadjuvant chemotherapy
Timeline
- Start
- 2022-12-07
- Primary completion
- 2025-08-06
- Completion
- 2028-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Doxorubicin | Other / unclassified | 75 mg/m2 | Intravenous |
| Subject | Ifosfamide | Small molecule | 9 g | Intravenous |
| Subject | Retifanlimab | Monoclonal antibody | 375 mg | Intravenous |